Literature DB >> 15156183

ETO interacting proteins.

Bruce A Hug1, Mitchell A Lazar.   

Abstract

The 8;21 translocation produces a fusion between the ETO gene and that encoding the myeloid transcription factor AML1. The AML1-ETO fusion substitutes the majority of the ETO protein for the coregulator recruitment domains of AML1. Biochemical analyses of ETO have led to the identification of numerous interacting proteins including many corepressors. Importantly, the proteins interacting with ETO are different from those of wild-type AML1, suggesting that altered coregulator recruitment underlies the oncogenic properties of AML1-ETO. The list of corepressors capable of binding ETO includes histone deacetylases (HDACs) and components of distinct HDAC core complexes. These investigations have provided mechanistic insight into corepressor recruitment by ETO and clues to the leukemogenic activity of AML1-ETO.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156183     DOI: 10.1038/sj.onc.1207674

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.

Authors:  Björn Lamprecht; Korden Walter; Stephan Kreher; Raman Kumar; Michael Hummel; Dido Lenze; Karl Köchert; Mohamed Amine Bouhlel; Julia Richter; Eric Soler; Ralph Stadhouders; Korinna Jöhrens; Kathrin D Wurster; David F Callen; Michael F Harte; Maciej Giefing; Rachael Barlow; Harald Stein; Ioannis Anagnostopoulos; Martin Janz; Peter N Cockerill; Reiner Siebert; Bernd Dörken; Constanze Bonifer; Stephan Mathas
Journal:  Nat Med       Date:  2010-05-02       Impact factor: 53.440

Review 2.  Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14.

Authors:  Lauren J Tracey; Monica J Justice
Journal:  Trends Genet       Date:  2019-05-23       Impact factor: 11.639

3.  ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.

Authors:  Daniela Salat; Robert Liefke; Jörg Wiedenmann; Tilman Borggrefe; Franz Oswald
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

4.  Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.

Authors:  Sangho Park; Wei Chen; Tomasz Cierpicki; Marco Tonelli; Xiongwei Cai; Nancy A Speck; John H Bushweller
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

5.  Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.

Authors:  Chun Guo; Qiande Hu; Chunxia Yan; Jinsong Zhang
Journal:  Mol Cell Biol       Date:  2009-03-16       Impact factor: 4.272

6.  Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.

Authors:  Benjamin E L Lauffer; Robert Mintzer; Rina Fong; Susmith Mukund; Christine Tam; Inna Zilberleyb; Birgit Flicke; Allegra Ritscher; Grazyna Fedorowicz; Roxanne Vallero; Daniel F Ortwine; Janet Gunzner; Zora Modrusan; Lars Neumann; Christopher M Koth; Patrick J Lupardus; Joshua S Kaminker; Christopher E Heise; Pascal Steiner
Journal:  J Biol Chem       Date:  2013-07-29       Impact factor: 5.157

7.  Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.

Authors:  Yizhou Liu; Wei Chen; Justin Gaudet; Matthew D Cheney; Liya Roudaia; Tomasz Cierpicki; Rachel C Klet; Kari Hartman; Thomas M Laue; Nancy A Speck; John H Bushweller
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

8.  Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.

Authors:  Chun Guo; Jian Li; Nickolas Steinauer; Madeline Wong; Brent Wu; Alexandria Dickson; Markus Kalkum; Jinsong Zhang
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

9.  The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain.

Authors:  Michael J Plevin; Jinsong Zhang; Chun Guo; Robert G Roeder; Mitsuhiko Ikura
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-27       Impact factor: 11.205

10.  CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

Authors:  Liya Roudaia; Matthew D Cheney; Ekaterina Manuylova; Wei Chen; Michelle Morrow; Sangho Park; Chung-Tsai Lee; Prabhjot Kaur; Owen Williams; John H Bushweller; Nancy A Speck
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.